PureTech gets grant for third U.S. patent for methods of treating infectious and allergic diseases

PureTech, a biotech medicine for immune, central nervous and gastro-intestinal systems producer, has gotten the United States Patent and Trademark Office (USPTO) a third U.S. Patent to Vedanta Biosciences that broadly covers methods of treating a variety of diseases including infectious and allergic diseases with mixtures of Clostridium live bacterial strains.
As the company noted in its press release on Tuesday, U.S. Patent No. 9,433,652 is the latest addition to Vedanta Biosciences’ patent portfolio after the issuances of U.S. 9,415,079 on 16 August, U.S. 9,421,230 on 23 August and earlier issuances in Japan.
PureTech noted that the patents are exclusively licensed to Vedanta Biosciences under an agreement with the University of Tokyo and provide coverage through at least 2031.
Daphne Zohar, Co-Founder and Chief Executive Officer at PureTech, said: “Together, we believe that these three patents solidify our IP leadership position in the immune-microbiome space.”